Combination of simvastatin and imatinib sensitizes the CD34+ cells in K562 to cell death
- نوع فایل : کتاب
- زبان : انگلیسی
- مؤلف : Rui Chen • Wei Xiao • Ding Li • Shijie Mu
- چاپ و سال / کشور: 2010
Description
Chronic myeloid leukemia (CML) is a hematological malignancy, 95% of which is due to translocation between chromosomes 9 and 22 and the resulting bcr-abl fusion protein. Imatinib specifically binds to the bcr-abl and inhibits cancer cells. However, a subpopulation of the CML cells named leukemia stem cells are resistant to the imatinib therapy, leading to the relapse. In this study, we identified a subpopulation of CD34? cells in K562 were much more resistant to imatinib than the bulk cells. Simvastatin single also had little pro-apoptotic effect on the CD34? cells. In contrast, combination of simvastatin and imatinib induced a significant cell death in the subpopulation, which is dependent on the induced ROS by simvastatin as the effect was blocked by ROS scavenger N-acetyl-L-cysteine (NAC). Our data here point out that combination of simvastatin and imatinib could be a therapeutic option for the resistant CML
Med Oncol (2011) 28:528–531 DOI 10.1007/s12032-010-9472-9 Received: 24 February 2010 / Accepted: 25 February 2010 / Published online: 31 March 2010
